EICHORCondition: Autoimmune Encephalitis · LGI1 Encephalitis · Limbic Encephalitis · Sponsor: Shen Chun-Hong
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study focuses on a rare brain disease called anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. In this condition, the body's immune system mistakenly attacks a protein in the brain, which can cause problems with memory, thinking, behavior, and seizures. While most patients get better with initial treatments, some continue to have long-term symptoms or experience a return of the disease (called a "relapse") months or years later. The goal of this study is to understand how often these relapses and long-term problems happen and to identify which patients are most at risk. The investigators will look back at the medical records of patients diagnosed with anti-LGI1 encephalitis at five major hospitals in Eastern China. The information about their symptoms, the treatments they received and how they recovered over time are obtained. Then, the investigators will analyze this information to find out what factors are linked to having a relapse or a poor long-term recovery. By understanding the risks for relapse and poor outcomes, doctors can better identify which patients need closer monitoring and more long-term treatment strategies. The results of this study will help create better guidelines for managing patients with this disease after their initial recovery, aiming to improve their quality of life in the long run.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Characteristic presentations of anti-LGI1 encephalitis; 2. LGI1-immunoglobulin G (IgG) positivity in serum and/or cerebrospinal fluid (CSF) by fixed cell-based assay (Euroimmun, Lübeck, Germany) 3. follow-up ≥ 18 months after initial immunotherapies 4. exclusion of alternative diagnoses Exclusion Criteria: 1. presence of coexisting neural autoantibodies 2. history of central nervous system (CNS) infections, severe neurological or primary psychiatric disorders 3. no prior use or lack of first-line immunotherapy 4. insufficient follow-up data
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China | Hangzhou, Zhejiang, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07722286